Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III TrialJohn C. Byrd, Wojciech Jurczak, Asher Chanan-Khan et al.|Journal of Clinical Oncology|2021Cited by 630
Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor‐experienced patients with paroxysmal nocturnal hemoglobinuriaPhillip Scheinberg, Austin Kulasekararaj, Diego V. Clé et al.|American Journal of Hematology|2024Cited by 42